Study register · detailKohortenstudie · Chronic Pain · 2025
How to ESCAPE from Pain? An Observational Study on Improving Pain and Quality of Life with the Cannamedical((R)) Hybrid Cannabis Extract.
Wagner et al.·Advances in therapyImpact 3.7
Clear benefitGRADEVery low0 citations
Samplen = 64 Pat.
Durationfour visits, exact time…
EndpointNRS
Blindingn.a.
DesignKohortenstudie
Cannabinoidkombination
THC:CBD1:1
Routeoral
”Key finding
Pain intensity and pain interference decreased in both groups, physical and mental health improved, high satisfaction reported.
Summary
Prospective observational study (n=64) on Cannamedical® Hybrid Cannabis Extract THC25:CBD25 in chronic pain patients over 4 visits; NRS pain intensity decreased from 5.46±1.73 (V1) to 3.37±2.43 (V4) in the ITT population; in cannabis-naive patients (n=35) reduction from 5.92±1.34 to 2.37±1.69. Pain Interference Subscore improved from 5.39±1.92 to 3.38±2.46 (ITT) and from 5.68±1.46 to 2.54±1.99 (cannabis-naive), respectively. SF-12 showed improvements in physical and mental health; high patient and physician satisfaction.
P
PopulationAdults (≥18 years) with chronic pain in Germany, n=64 (ITT; 50% female), of which cannabis-naive subgroup n=35
I
InterventionCannamedical® Hybrid Cannabis Extract THC25:CBD25, oral/extract, in routine clinical practice
O
OutcomeNRS pain intensity decreased in ITT from 5,46 to 3,37 (V1→V4); in the cannabis-naive subgroup from 5,92 to 2,37; pain interference subscore and quality of life (SF-12 physical and mental) improved in both groups
Confidence in the evidence
Very lowLowModerateHigh
Very low
The lowest GRADE level, the effect estimate remains uncertain.
Downgraded for
Imprecision
Quality profile
Sample size★★★★★
Blinding—
Effect sizeClear benefit
Citations / year★★★★★
Authors
Wagner Y, Samel I, Probst K, Schollenberger L, Ruckes C, Nadstawek J
Introduction: Chronic pain remains a challenge, with standard therapies often providing inadequate pain relief and causing undesirable side effects. Medicinal cannabis has emerged as promising alternative. This study assessed the impact of a cannabis hybrid extract on pain intensity and quality of life in daily clinical use.
Methods: ESCAPE was an observational study and included patients aged >/= 18 years with chronic pain in Germany. The primary objective was to evaluate the effectiveness of the Cannamedical((R)) Hybrid Cannabis Extract THC25:CBD25 on pain during four visits (V1-V4) in clinical practice, and key secondary objectives were pain interference and quality of life. Pain intensity was measured using the Numeric Rating Scale (NRS) of the Brief Pain Inventory (BPI) questionnaire. Pain interference was evaluated with the BPI pain interference subscore, and quality of life-particularly physical and mental health-was assessed with the Short Form-12 (SF-12) questionnaire. Additionally, patient and physician satisfaction with the extract was assessed.
Results: The study included 64 patients (50% female) with chronic pain (intention-to treat population; ITT). Cannabis-naive patients of the ITT were defined as a subgroup and analyzed separately (N = 35). Mean (+/- SD) NRS-assessed pain intensity decreased during the study, in both the ITT (5.46 +/- 1.73 at V1 vs. 3.37 +/- 2.43 at V4) and in the cannabis-naive subgroup (5.92 +/- 1.34 at V1 vs. 2.37 +/- 1.69 at V4). Mean pain interference subscore decreased between V1 and V4 for the ITT (5.39 +/- 1.92 vs. 3.38 +/- 2.46) and the cannabis-naive group (5.68 +/- 1.46 vs. 2.54 +/- 1.99). Physical and mental health improved in both groups and high satisfaction with the hybrid cannabis extract was reported by patients and physicians.
Conclusion: Treatment with the Cannamedical((R)) Hybrid Cannabis Extract THC25:CBD25 in daily clinical practice showed positive effects on patients' pain and quality of life.
Trial Registration: German Clinical Trials Registry identifier DRKS00026906.